ANI PHARMACEUTICALS, INC Research and Development Asset Acquired Other than Through Business Combination, Written-off
ANI PHARMACEUTICALS, INC (ANIP) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $929.43 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2013-02-28
- ANI PHARMACEUTICALS, INC research and development asset acquired other than through business combination, written-off for fiscal 2012 was $929.43K.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|
| 2012-12-31 | $929.43K 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |